0001092662-12-000016.txt : 20120418 0001092662-12-000016.hdr.sgml : 20120418 20120418172129 ACCESSION NUMBER: 0001092662-12-000016 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20120418 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20120418 DATE AS OF CHANGE: 20120418 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CHEMBIO DIAGNOSTICS, INC. CENTRAL INDEX KEY: 0001092662 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880425691 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30379 FILM NUMBER: 12766627 BUSINESS ADDRESS: STREET 1: 3661 HORSEBLOCK ROAD CITY: MEDFORD STATE: NY ZIP: 11763 BUSINESS PHONE: (631) 924-1135 MAIL ADDRESS: STREET 1: 3661 HORSEBLOCK ROAD CITY: MEDFORD STATE: NY ZIP: 11763 FORMER COMPANY: FORMER CONFORMED NAME: Chembio Diagnostics Inc. DATE OF NAME CHANGE: 20040607 FORMER COMPANY: FORMER CONFORMED NAME: TRADING SOLUTIONS COM INC DATE OF NAME CHANGE: 19990805 8-K 1 form8_k.htm FORM 8-K FOR PRESS RELEASE form8_k.htm  


 

SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported):  April 18, 2012 (April 18, 2012)


CHEMBIO DIAGNOSTICS, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
 
0-30379
 
88-0425691
(State or other jurisdiction
 
(Commission File Number)
 
(IRS Employer
of Incorporation)
     
Identification Number)
   
3661 Horseblock Road
   
   
Medford, NY 11763
   
   
(Address of principal executive offices)
   
   
631-924-1135
   
   
(Registrant’s Telephone Number)
   
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
 
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
 
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 


 

 
 
 
 



ITEM 7.01.                                  REGULATION FD DISCLOSURE.

On April 18, 2012, the Company issued a press release entitled “Chembio Reports Completion of Enrollment in Pivotal Trial for DPP® Point-of-Care HIV 1/2 Test”.   A copy of the press release is furnished herewith as Exhibit 99.1.


The information in this Item 7.01 of this Form 8-K is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.


ITEM 9.01.                      FINANCIAL STATEMENTS AND EXHIBITS

Exhibits.

99.1
   
 
 
 


 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


April 18, 2012                                                          Chembio Diagnostics, Inc.



By:    /s/ Lawrence A. Siebert                                      
Lawrence A. Siebert
Chief Executive Officer
 
 


EXHIBIT INDEX
 
Exhibit Number
Description
99.1  



 
 
 
 


EX-99.1 2 ex99_1.htm PR FOR ENROLLMENT COMPLETION ex99_1.htm  


 




Chembio Reports Completion of Enrollment in Pivotal Trial for
DPP® Point-of-Care HIV 1/2 Test

Expects to File Final PMA Module with the FDA in June

MEDFORD, N.Y (April 18, 2012) – Chembio Diagnostics, Inc. (OTC-QB: CEMI), a company that develops, manufactures, markets and licenses point-of-care diagnostic tests, today announced completion of enrollment in a 3,000-patient clinical trial in support of a Pre-Marketing Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Company’s DPP® HIV 1/2 Assay.  This product is a rapid point-of-care test for the detection of antibodies to HIV 1 and 2 in oral fluid, finger-stick whole blood, venous whole blood, serum or plasma samples that provides a simple “reactive/non-reactive” result.  The test is intended to be used in the preliminary diagnosis of patients with HIV in point-of-care settings such as public health and other clinics, hospital emergency rooms and physician offices.  The DPP® HIV 1/2 Assay delivers visual results within approximately 15 minutes, is simple to use, has a shelf life of 24 months and does not require refrigeration.

The DPP® HIV 1/2 is based on Chembio’s patented Dual Path Platform (DPP®) technology.  The DPP® enables samples to directly bind with target analytes before detection reagents are introduced to visualize the test results and can improve accuracy compared with the current lateral flow HIV test technologies.  In addition, a proprietary sample collection system in this assay enables each sample to be contained in a convenient, closed collection vial, or Sampletainer™, which provides more testing flexibility over other systems that do not have separate sample collection or that use open vials for stirring blood samples.

“With more than 1.1 million Americans estimated to be living with HIV and approximately 20% of them unaware they are infected with the virus, rapid HIV tests are playing a critical role in the U.S., as they have globally, to help identify those with HIV and to prevent disease transmission.  Anti-retroviral medications allow many individuals to effectively manage their disease and have increased patients’ desire to know their status.” said Lawrence Siebert, Chief Executive Officer of Chembio.  “Now that enrollment in our pivotal trial is complete, reference lab testing will be completed and the clinical sites will be closed by early May; within approximately 30 days thereafter we expect to finalize and submit the third and final module of our PMA application to the FDA.  This final module is principally comprised of this study’s data. We believe that the product will meet the required performance on all sample matrices.”
 
 
The pivotal study involved five clinical sites across the U.S. and was designed to include various patient groups as required by the FDA to support the sensitivity and specificity of the product across various demographics.  In addition to clinical data from this study to support field performance, the other principal components required for PMA approval are non-clinical data, manufacturing data and a pre-approval inspection of the manufacturing facility.

The FDA accepted Chembio’s shell application for DPP HIV 1/2, proposing a modular PMA submission plan containing three sections or “modules.”  This approach divides the PMA application into modules filed at different times that together form the complete submission.  This approach allows the FDA to review each module separately as soon as it is received, making it possible for manufacturers to receive timely feedback during the review process, and perhaps shortening the time to a regulatory determination.

Chembio submitted the first two modules containing the preclinical data, prior clinical testing and a quality manufacturing system review to the FDA in April and October 2011, respectively.  The Company expects the pre-approval inspection of its manufacturing facility to occur during the second or third quarter of 2012.

About Chembio Diagnostics
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $7 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere North America, Inc.  Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors.  Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP®.  Headquartered in Medford, N.Y. with approximately 160 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U. S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485. For more information, please visit: www.chembio.com.

 
 
 
 
Forward-Looking Statements
Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended.  Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management.  Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed a review or audit of those results.  Actual revenue may differ materially from those anticipated in this press release.  Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties.  Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, Chembio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner and the demand for Chembio's products.  Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.  Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Contacts:
Chembio Diagnostics
Susan Norcott 631-924-1135 x125
snorcott@chembio.com

Investor Relations
LHA
Anne Marie Fields
(212) 838-3777
afields@lhai.com
@LHA_IR_PR

# # #
 
 


GRAPHIC 3 cdi_logo.jpg begin 644 cdi_logo.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X1)317AI9@``24DJ``@````'`!(!`P`! M`````0`V,1H!!0`!````8@```!L!!0`!````:@```"@!`P`!`````@!N9S$! M`@`>````<@```#(!`@`4````D````&F'!``!````I````,X```#`QBT`$"<` M`,#&+0`0)P``061O8F4@4&AO=&]S:&]P($-3,B!-86-I;G1O7U5F9VAI:FML;6YO8W M1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,% M,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55 M-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=W MAY>GM\?_V@`,`P$``A$#$0`_`.\Z[UY^`]F'AU>OG6M<]K>S0![?^,ML?[:Z MO^N?\;DVMRL_ZOVYSKK7/-3OYTEI%K?T;IHJMPM;1;ZF/O?8QS@/<7?2H&Y2_8UI2LDR/I(](>=Q^O]=Z-L-5]UQ:XBUN2]UM+FG^:K#7^_'? M_.>]EJ]'Z+U>CK&`S+I&PR66UDSM>W1[=^GJ,_T=G^$K7.,.'14<4N%A,V.Q M@TN?(FT67-ES;ME;&5;J_P!`K.%U/"Z7GOMS;Z\7'R*@"^PAH-C"/2;K^?Z3 MK$H=.^L/7.B=-Q,FO+PSJ_^8 ME($3J=C3B^:)[QDN&",2#"X5VVEYAJ]-ZEB=3QSDX;B^H/?62YI:=S#L?[7A MKOI!+.ZCB8'V?[2XM^UWLQJ8:7399N]-IVCV_0^FYXUN#B0'6/+?HM=])$ZW]8^B=6R.C8_3LMF1:SJF-8YC0X$-'J,W>YK?S MK&)QY:7NF/#+@!/JKI_>6C/'VQ+BCQ5M;LYWUMZ)@9EN%DV6"^C;ZC64V/`W M-;:SWU,>WZ#T_3_K5T;J66W#Q'VNN>'.:'4VL$-&YWOLK:Q9%?7ND]'^M?73 MU+(&/ZYQ/2EKW3LI]_\`--?]'U&+8Z?];/J_U++;AX66+LAX+FLV6-D-&YWN MLK8U*6("-C',^F,N._1ZH<7[GZ/]]4 M'MKL?4^.SZG.JM8?ZKV(RX?ZFY^1C9=;\ETXOUC=?DXY/YF3798+:O\`T(QA M7;N_X/TUU'7NJMZ3TJ_-V[[6C9CU?B6LR'U6![<1[J[RT$[7L:VRQG\K8U_YJQF?7SZL.#7 M')?6QT18^FUK=?\`A/2VJE]5Z=DT,N>=?\`A&O5 M3HGUN^KN!]5,;#R[A?D5X^RS##2XN)G]"[ MF<>+C^63'[QJ-F,+$B>+O&7#P_,];G=6P,'!'4+[)Q7%@;96#8#ZI:RIS?2W M[FOW_21,[/P^GXSLK-N;10SZ3WF!_5;^\_\`D-7'9V!D]/\`\7>-B94>LRRE MS@UP>`'Y#;F,#V^U^QC]OM6C3CU]>^M69;F`6X71-E.+0X2PWO;ZE^18T^US MZOYMB;[,`#+B)C&4[D/THPX(PX?[W&N]V5@5ZI"-`]#+BXN+^[PI_P#GOTHM M]88V<[$_[F#&L]&/W]\;]G_6UL=/ZC@]2QAE8%S"[%R/3^CZN_?ZC__`$K:F@8YV(@P ME1,=>(2X?T4DSAJ2)1O73AX7_]"Q]9L?(Z3UZVBUQ;TWJ-WVIKS)#7/]N5:S M;_A:76/WU^]CZO1]6M-UB@=)=3?3:V['L>/3KLU<=L6&=@;7;CN;L]W\M=A] M:,[ZL>C^S.O/+1G8W_7]&N&ZM3T;*O:^CK@LKK8V MJIE^->"QC1[6[Z:=K_WG?HJUJ8,AF(<49"A4CPRE')^[*XN=G@(WZ&]6/J%C9F=3;U M'J)]:C6K%]03NEV^^WW#Z#'[::?^O5K`Z9A?5&N/VIUA^13(><2FC(KK+AI- MCS6Y[_;^YZ+UV5?UV^J55;:JLKTZZP&L8VBX-:T#:UK6MH]K6J/."(RABQS/ M$?FX)^F/[L>)?AEQ&,\N2(X1\O''UR_>DTOKOBNP3T[KV'4V.F7`WL8`V:WE MGTB/S=S/1_\`0A=/A9F-G8M69BO%E%S=S'#\A_=>QWL>S\QZS,;ZU?5SJEPZ M?3?]HLR`YOHNIL#7C:YUC'>M4VK;Z;7?360?JQG=,O?=]6.I'#KL,NP\@;ZI M\G_I?S0UGOJ];_NPH.'BA&&2\.LD)?,($>F4?W7L56 MLZC@59E6!;?6S+O:7U4N<`YS6F#M;_K_`(3_`$5BYQW_`#_N;Z9R^GXH[W5A MSW?)CVVL_P"@K'1/JY@],RG=0R[W]1ZF_G+N_-_-_0LS]'O<][]GZ.O MTZOT:9[48@F4P37ICC]6OC)?[LB0(Q('Z4I^G[%_J,QCNANW-!_6LGD?\*Y2 M^MC&-=T3:T#_`"MC<".UJ?\`;'U6^K0_9[K78NZ.9$5Z(QC\W'_52.,`Q]-$R/%Q:^N7%\O"B9T-^5]2<#%Q MCZ>;C449.&_@MR6-%S.8^F]SZG;O](@].SO^=?5<+(V%F%TJIN1?600#GV`M M;3[OI?86>H_?_I'K4R_K1]7NDV#"RL@T/J8TBL5VOAA'Z/WU5V-^B/WU;PV= M/Q&VG%K],9-CLFV/SK+8<^WW._/1,Y",C*$KD92QR(_SG\X@1B2`)#T@#)$? MU/E<=WZO]:NKTCC-Z;7DGXTFW%_ZER-]4L?&O^J/3F9-3+:S1[FV-#@1+OI! MZOVXO3+LW[=963D^B[&WASA^B>=[Z]C7[/I?G;=ZRO\`F9]3X`.$X@:0;KB/ MN]=+CC*-'BB?1K&/%_-QX/WX*X9"5CAD/5H37SGB_=D\[>:V]"ZUCX#R_H]' M4<=N`9W-!-E3LJNAW^@;8?T:Z"O(K^K_`-:,MF:15@=;++L;(<88V]C?3NQ[ M7'Z#K?YQBT,_%Z`WH[L3*I%73,8"UU=>Y@:*W>MN#<8^K]/W^SZ:I9GUN^I> M=COQE])L%7J.VU M4LIM:"XCESWU-]_M_G+7IHQ''[&=1,H`7K4^(R_JA M_]'T3,ZJ_%S/1-(?0P4FZW?#FG(L?C4[*=FVQK;*_P!+^F9[/YMEJM9F5]EI M;;MW[K:JHF/YZVO'W?V/5WK)ZGZ7[=QI^R>I^AV^OZF^-]T[=OZMZO\`Y7^K M^D];[0M/J,?9V;O3CU\?^>G;/K51MV?X;_N/_P!V/23R8>G3^\L`GZM?[J7* MR:L3&MR;CMJI8ZQY\`T;BH=/S&9V'5E,&WU![F2';7M.RZK>SV/]*UKZ_8A] M6V_8QN]*/6H_I$^G/K51.S_"?Z'_`(?T]Z;IFW]:CT9^TV3Z$Q/M_G=W_:C_ M`$^S_"IOIX>O%?X+O5Q=.&OK:(]7C-]'96W&%PQ3=9;L>;BP6AE-!9ML^FRO M^?KM_G/3I_TI^HYPP:F6FIUP?8VLMK$O`=])[:Q[K?3;[_39^D?_`(+])^C6 M:_T?^M+J&W]6GTOZ17'JSSK M_,[/\/\`Z/[(;NQPW#LR'XE5V^7FVLV,<78^SVT^K1;6U_KOL_F_T/I_ MS9^EQ]F?'H_S^1_1Y]/^>M_>_P`/_P!R_P#NWZZR\?T?V\8^R>M]HMW;?5G; MZ3?YK=^I_M3_`+F>G^F^Q)`PN6AK]%1$ZC1']9U>J9MF#ANR*Z?7+2`1)#6M M)]UMAK9?;Z;/SO2HN_[;WV,L->'U"RO:_(_NUIYH>EY=N;ALR;JFTN>7#8UYL$-)9],UT_N_N*>'E#*; M:=FSTK7T\S.P[-_]I0Z5M^P5[?2B7?S$^G]-WT-_N_K_`,M+IVW;?'I?TBV? M1F)W?X7?_A_]*D3'U4*U]/@%`2]-F]/5XE;$S;\JZTLH:W#K>^IMQ?[W/J=Z M5GZN&;6U>JVUF_U_4]G\RFZCGNPG8Y](.JNL#+;G.+65@]WEC+?<_P#P7J>E M1_IEZVYT^EZOT=F/_/3^I_;O]+_A_LOV5-U[TO6Q/4^S MG_`(/^M[/6])64U?YFQC?Y/Z2NWZ%U7Z2I%P=O['QX]+;]F9 M'I;O1C8/YK=^D^S_`+F[W^FJ_3-OVFN/LO\`0<>/0W>I$V_O?]H/^X6_])_2 M4ZX>K0Z_+X(J7IU&GS?UFS=FWC.&'C4MMYU;/3AEKKK7^E= M[/T=?Z/WW*XLGJWH_;\3U?2F#LGU?5W>I1$_9O\`M%_I_M'ZO]H^R;UH7;?4 MHW<^H=OTN=EG[GM^C_I?T?\`UWTT#PT*T[J'%9O7L__9_^(,6$E#0U]04D]& M24Q%``$!```,2$QI;F\"$```;6YT`",`*``M`#(` M-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D M`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE M"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+ M(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U` M#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/ MLP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)% M$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5 M-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA` M&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH; MLAO:'`(<*AQ2''LP>%AY`'FH>E!Z^'ND?$Q\^ M'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC M."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<`^(#Y@/J`^X#\A/V$_HC_B0"-` M9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B M1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I, M%W)7AI>;%Z]7P]?85^S8`5@5V"J M8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG/6>39^EH M/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO>&_1 M<"MPAG#@<3IQE7'P,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_Y8!' M@*B!"H%K@%JX8.AG*&UX<[AY^(!(AIB,Z) M,XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1 MDGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*; MKYP0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4X MI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:O MB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG" MNCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$ MSL5+QHM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFENV<[BCNM.]`[\SP6/#E\7+Q__*,\QGS MI_0T],+U4/7>]FWV^_>*^!GXJ/DX^'EZ@X2%AH>(B8J2DY25EI>8 MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;G MZ.GJ\?+S]/7V]_CY^O_$`!\!``,!`0$!`0$!`0$````````!`@,$!08'"`D* M"__$`+41``(!`@0$`P0'!00$``$"=P`!`@,1!`4A,08205$'87$3(C*!"!1" MD:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6F MIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V M]_CY^O_:``P#`0`"$0,1`#\`]^9@JEB0`!DDGI7&ZAXQ>YOK>ST=5*RES]ID M'WE3`8QKWY*@'H>3TP2>.+RXN8QHUF)-S)YLYC?9D9^6,L&!`;!SM.<8Z@D5 MQS^'(+@R;$:*\M(_,RI.QTWE<9/W6``/!//R\XS790HP:YIG)6JS3Y8(Z2\2 M[N;69KB\OG&QBVRX=#T[!2`#^%>;:;KVOQZF`FNW=BCEF'FS/+%&`"V-KD@\ M#'/7O7LMU+$-'0`9N;B$;`@&2S#K[<_YS7F%QH+7E\EE$B^8[;>>BXZG\.:Z M\+.#4E)'-BZ#+RWU.,V<`GC/8D=!6.,H4DN>E\T:8.M6?N55\SMJCFFCMX7FF MD2.*-2SNYPJ@2?%?Q%+/>0^&K(LP^62X6/DR.3^[CQ^38[DKZ5R4 M*+K34$=5>LJ,'-B>(/BE>WMU]@\+P-\S;$N#%YDLI_Z9QXX_$$GT%4X?`WCO M6QY^HZD\`;G9=WCLP^B+D#Z9%=YX)\&6WA?3P\BI)JN>^,` M6/AG>W5_X/6>\N9KF8W$@\R:0NV`>!DUA.E&TIP?NIV-J=65XPFO>:N=E117 MG?B34;Z#XK:!90WMQ':RQ(9($E8(Y+2#E0<'H/RJ*=-U&TNS?W&E2HJ:3?>Q MZ)17E_CZ?5IO'.DZ3IVK75B+J!5S%,RJ&+MR0I&>E/\`^$"\8_\`0[7/_?V; M_P"*K58>/*I3FE?U,7B)VL18R6[22 M$291@."Q'!(/X4[7_%;:+\1-)L)I"+&>VVS`_=5I'(1_P*8]@QJ/8WERP=]+ ME^VM'FFK:V.YHHHK$W"BN)^)7B>3P]H"16YGA?_EW9T=3_LD@BK=.2BI/9F:J1P M+',82KSRL20JG.0W^U^E:%QK'B[P!?6S:W=#5=(F;:9!\S+ZX8@,'`!.#D$` M]#DCIEA/><(R3DNFISK%^ZIRBU'N>LT5R_CV]EM_`NH7=EQJ;P?>/)X(TV\O;AG;[/OEFF?)P"J2^%OB#JD,\;R6%U,+@HH&[#J"73G M^]D'D9VU1^U:GK2*R2'45A0-OMU"A=W!4H<$,"IQP<@"O2C1;BG>R:1PO$13 MM;WDV=$=1+Q!6L+AG"*LNUF8X`#`J<^W.:H M:G0:&JZW\ M9IIY2LL<=Y/*ISD,(]RQD'VPA_"NU_X51X6_YXW7_?\`-$$M[[5K"UG$\C&.>Y1'P3P<$Y MKLO%'_(I:U_UX3_^BVKS[P!X*\/Z]X86^U*Q>:X,TB;A<2)P#QPK`5V4N3ZO M+GO:ZV^9Q57/ZQ'DWL]_D=]_PEOAK_H8=)_\#8__`(JN"UO4;'4_BYX=GT^] MMKN)8T1GMY5D4-ND."1WY%=1_P`*Q\(?]`IO_`N;_P"+KC[_`$+3O#WQ7\/V MFEP&"!U25E,K/EBSC.6)/0"KH*BF^1N]GO;MZD8AU>5Y@LO MBEX>N;F58H(HD=Y&.`HWOR:['_A.?"__`$'+/_ONN,\=V=OJ'Q/\/V=U'YEO M-"B2)DC<"[]QS74?\*V\(_\`0(_\F)?_`(JE/V7LZ?M+[=+=V$/:^TJ>SMOU MOV1I6?BO0=1O(K2SU:VGN9<[(T?);`)./P!/X5YGXLTB;Q7\0]RA&V?CYA'UKT33?`_AS2=0AO['3O*N8"Q'0D5S/@,_;? M'GB_4"0=L_E(P[KOK,!PW_`A@_7([5U1->7M_Q0_Q0#_O]U)"W]';Z!9 M?:MOXEZ\^D^'/L5MN-]J1-O$J?>V_P`9'O@A1WRXK.I1YJJY-I:K]?N+IUN2 MD^?>.C_3[SSWQ&T_C.Z\0>((F8Z=ID<<%L1T<>8`3T[J7?U&Y*]2T:Z^V?#F MTG)RS:8`Q]6$>#^H-4(_#"Z1\,+W1PBM<-92O*P_BF*$Y]\'`'LHJKX"N1WEG?6ZF01"4D2`H)]"2#T(&IC7)8 M#ZG:/<$BK]WXCE\3?!S4KJZV_:H7C@G*C`9A)&0P';(8?CFL+Q+')%\//!NH MJNY+GR\L)[J3_`"'B*BDY2ALX_J>L^&-"A\.:#;:=$%WH MH:9P/]9(1\S'\>GH`!VK8J*">*ZMX[B!P\4J!T<=&4C(/Y5+7F2DY-M[GIQB MHI);!7D]I`/!_P`7TLK4>7IVJQY$2_=4-NP`.G$BD#T5OS]8KRSQ(XU+XS:' M9P$,UHL;2X_A(+RD'_@.T_C73A=7*+V:=SGQ6BC);IJQI_$WPE+K>GQZG8Q& M2^LU(:-1EI8NI`]2#D@=\L.217`^`]52*XETYD&)SYJ2`="!R#[8''OGUKWZ MN/UCX?V-[JHU?3W^Q:AEC(57,QYZCWR#6N'Q:C3=*IMT?8RKX5NJJ MU/?KYGF7CB>R2]ABMXXQ>!SS6/X9NQ;^)K&1W**\AC M8CON!`!]LD5MZC\-O&`NGD:TBOG=MS2PW"`$_P#`RI_2FVGPP\5W,FV2RAM% M_OSSH1_XX6->I"K05+E5.E7E7]HH/<;XXO[>XNQ:>:^^T7)4$[2[$9!&. M-J@_]]@=CGT#X9>$I-$TZ34K^(QW]XH"QL.8HNH!]&)Y(]E'4&I/"OPRT[09 M8[R\D^W7T9#1DIMCB/JJ]S[GT!`%=U7F8G%1=@??3USU('3Z8)[2O+O$GP MG$MP;WP[-';/NW_9)"516ZYC8\0Z=X;T]KO4)@HY$<:\ MO*W]U1W/Z#O@5YH_BKXE:E^ZM]&EM6/\2:<\?ZRDBC3OAEKNMWWV[Q1?/%N^ M\OF^;.P_N[N54?3/T%)86$'>M-)>6K*EBISTHP;?GHCHK3Q@GBWP-X@D^Q2V MLT%E,LB_>C.8V(VO@9.,9'!&1V()F^%'_(D1_P#7Q)730:%IMMHK:-!:K'I[ M1-$T2DC*L"&RV';BYE2& M&*)&>1SA5&]^2:[7_A,O#/\`T'M._P#`A?\`&C6O!VA>(;J.ZU2R:>:-/+5A M/)'A'[F816^L64TI#,(XY@S$*"QP/8`G\*Y+X/1L_A_4;Z3_67%X=Q]<(I MS^;-6[:_#OPO97`GM]-=)0CH&^U3'`=2C=7_`+K$9[9XK:T?1;#0;'[%IL!A MMPQ?89&?D]3EB342G3C"4*=];;^12A4E.,YVTOMYF-X]\/?\)'X7GMXTW7^-O%,&M:H?,@TFWCCC)Z/*!PQ]3GVQ;=%D0JX!5A@@]Q7EWPT

$O$6FNIUCV/AG2 M--FU&6TM3&^HDFZ_>N1(26/`)^7[[?=QU^E3"HHPE%];?@74IN4XR72_XG!? M"W7]'TGPO/!J&IVMK,UVSA)I0K%=B#.#VX/Y5L^)?B7HMEI,ZZ7>)>7SJ4B$ M8)1">-S-C&!UQU/ZBZ/AAX0`Q_9+?^!<_P#\75_3/!'AS1YUGLM*A69#E))" MTK(?4%R<'Z5O4J8:51U+-^6AA"EB(TU332\]3@(M"N-#^"NIB\B:*>[ECG\I MQAD7?&J@^APN<=1G!Y%=1HNB0>(?A58Z9<-L$ML-D@&3&X8E6'T...XR.]=5 MJ>EVFLZ=+87\1EMI<;T#LN<$$%=L:%BV!]22 M3^-1/$N4?[U[EPPRC+RM;\3S+PSXMN?!=R?#/BJ*2**'_CWN`"X5.W09:/KA MATZ$#&%]%M_$&CW40E@U6RDC/\2W"'^M2:IHVG:W:BWU*SBN8AR!(O*GU4]5 M/N*Y*;X2>&9)=Z?;8E_N),"/_'@3^M$IT:KYI7B_+5"C"M27+&TEYZ,D\3?$ MK1](MGCT^>+4+\\1I"VZ-3ZNXXX]`<]N,YJO\/?"]];7%UXCUS?_`&I>YVI( M,-&C')+#L20/E_A``XR0-[1O`_A_09EGLK!3VR6QC>)?#=IXITL:?>37$40E67=`5#9&>/F!&.?2N2_X4 MUH'_`$$-5_[^0_\`QNNG\43WD46F0V-[)9O=7Z0/+&B,P4JY.`ZD=0.U/T"] MO)+C4M-OYDN+BPF5!<(FSS$9`Z[EZ!AD@XXZ'C.`H5:M.'NRT'.G2J3]^-V< MK_PIK0/^@AJO_?R'_P"-T?\`"FM`_P"@AJO_`'\A_P#C==9XJO+C3O"FJ7MG M+Y5Q!;.\;[0VU@.#@@@_C6U5?6J]K\POJM"]N5'G/_"FM`_Z"&J_]_(?_C=' M_"FM`_Z"&J_]_(?_`(W71^,-8N=+TV&+3Y($U*[E\NW,[!4&T%V+$]!M4KGU M9?6M?3-1@U;2[74+8DP7,2RIGJ`1G!]".A'K3^LUU'FYB5A\.Y6.>*WO$6HRZ5H ML]U;I&T^Z.*+S/N!Y'6-2W^R"P)]@:R[2YFTWQ%!IEYXCGO9KB,_N)[$("X! M;,6@U1HPEI%7-3^P++^XG_`(#0_P#Q%']@6?\` M<3_P&A_^(K6KSV;Q;J-GI.O+=D12!M072[U5!!>(R8B<$8#@+E<\,H]0QK-QCN=9_8%G_<3_P&A_\`B*/[`L_[B?\`@-#_`/$5I0$M;QLQR2@)/X5A M:K<7UYKUMH]E>M8+]G:ZGN(XT>4@,%5$#@J.2220<8`[Y$J[93LD6_\`A'[+ M^XG_`(#0_P#Q%8&M_#31]=O4N[BYO(76,1!;<0HI`).<>6>?F/Z5KZ%=W@U# M4M)OK@7:3H#7#6T]S,9PH87*PR8VYQC]V,?>/Z5 ML_\`"/V7]Q/_``&A_P#B*SO"5[>S)=6VIW=X^H0I&T]M=V\<;0E@02C1@*\9 M*G:1DC:.*SM9N+V;5K#2+&Z^QM<12W$MTJ*[K'&4!5`P*[B9%Y((`!XY%$7 M)2T>P-1<=5N<[;?"+0;6[@N4OM39X95E57:(J2I!`(\OD<NKTZUN+2U\JZOI+UPQQ-+&B.5SP#L` M4D>H`^E7*B6)K23BY:%QPU&+NHJYG:MI$&LP0Q32SQ&&831O`^UE8`@V:WM5?#N9)))7+R2N<99F))8\`?0`#``%%%8X_4].@U;3 M+G3[G=Y-Q&8WV'!P?0UP65[DE]96^HV4U MG=Q++;S(4DC;HRG^59NG>'+>RO5O7O+^]GBC,<+7DYD\E3UV\=3@98Y8XZ]: M**7/)/E6PK-NL>3PUIL^CWFE3Q&:TO)99I56>WN;?=Y-S;2;)$#8W#/0@X&001P# MC(%%%)-IW0FDU8?I6D6VD12K`TLDD[^;-/.Y>25\`98GV```P````*LW=K#> MVDUK<()(9D:.1&Z,K#!!_`T44-O<:2V,_2=!M]'::5+B[N9I52,RW4N]PB9V M(#Z#V34]Q;I=6 MLL$F=DJ%&QUP1@T447ZCMT&VELEG9PVL6?+AC6-<\G`&!FJNJZ-;:NL)E>:& M>W;?!<6[[)(B1@X/H1P0<@]Q110F[W!I6L3:?9?V?9K;_:;BY()8RW#[W8DD M\G\>```!P*9JNEP:O9_9IVE3:ZR))$VUXW4Y5E/J#^'8\4447=[A96L+I>EP M:19_9H&D<%VD>25MSR.QRS,>Y)/T'08`J&X2:77+/%P\<$4,LC1+QYC':JY] M@"W'